Linda T. Nieman

This study identifies Dusp5 and Zfp219 as key regulators of age-related T cell dysfunction using CRISPR screens and shows their potential as therapeutic targets.

In metastatic breast cancer on TROP2- or HER2-targeting antibody-drug conjugates, early CTC disappearance or steep decline tracked response, while CTC epitope levels neither predicted benefit nor vanished at resistance.

This study identifies TROP2 as a regulator of tight junction-mediated immune exclusion in TNBC, showing that targeting TROP2 enhances anti-PD1 therapy response.

This study identifies a novel CD8+ TIL subset that uses lymphotoxin and IFN pathways to kill cancer cells, linking LTB expression to clinical response in melanoma.

The paper generates a multi-modal atlas of thyroid and blood cells from HT, GD, and controls, revealing shared immune niches despite distinct disease mechanisms.

This study uses high-throughput microfluidic technology to enrich CTCs from large blood volumes, enabling detailed molecular and morphological analysis of tumor cells in metastatic cancer patients.

This study uses single cell spatial transcriptomics to show LINE1 repeat RNA expression in HCC correlates with a disorganized immune microenvironment and poor patient survival.